Introduction {#s1}
============

Parkinson's disease (PD) is a common neurodegenerative disorder that leads to a syndrome that is related to neurological control of movement as well as other brain functions including cognition ([@B77]). Due to the high prevalence and poor treatment, it is associated with an increasing socio-economic burden occupying a wide spectrum from minimal disability to marked impairment of capabilities with respect to independence, safety, and communication ([@B24]; [@B40]). The development of PD is mainly connected with aging. However, there have been other confirmed risk factors that influence the occurrence of PD.

First and foremost, protein pathological hypothesis displays complex and distinctive pathophysiological profiles: accumulation of aberrantly processed and misfolded proteins, such as amyloid- β (Aβ), tau, α-synuclein, TAR DNA-binding protein 43 (TDP43) ([@B16]; [@B20]), and mutant forms of Huntingtin (Htt) ([@B10]). The clearance of these proteins is impaired ([@B14]), which aggravates the pathological accumulation aberrantly and neurotoxic effects ([@B47]). Next, oxidative stress and neuro-inflammation cause non-autonomous cell death due to complex multi-factors interaction, including α-synuclein accumulation, ubiquitin-proteasome system dysfunction, and metabolic disturbances ([@B17]), such as hyperammonemia ([@B13]). There is strong evidence that demonstrates that enteric nervous system is involved in PD pathological progression toward the central nervous system. Gut--brain axis suggests that PD starts in the enteric nervous system and spreads to olfactory bulb or brainstem, a process that antedates degeneration of the dopaminergic nigrostriatal system ([@B27]; [@B22]). Among the reasons for this are involved in interacting with the microenvironment \[outer: microbiota ([@B45]), metabolites, and nutrients ([@B30]); inner: immune cells ([@B52]) and inflammatory cytokines\] of the gut and specific living conditions ([@B21]). In addition, the above several aspects are ascribed to the root of genetic susceptibility. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with the highly penetrant autosomal dominant or recessive PD ([@B73]). Recent studies have shown that genetic variants can influence cognitive abilities. The ensuing molecular insights have contributed to substantial advances in our understanding of the pathogenesis of PD. Further mechanism studies have shown that NUS1 loss can reduce the number of dopaminergic neurons and the dopamine level, and induce apoptosis events in the brain of fruit flies ([@B26]).

Research on genetics, however, has always been hampered by inadequate sample size. Meanwhile, gene phenotypes might be better targets for exploring the etiology and pathophysiology of PD. Although the diagnosis of PD relies on the presence of motor deficits and clinical effects of dopamine therapy, this disease is closely related with non-motor symptoms and signs before the onset of the classical motor symptoms. Indeed, some evidence has suggested some of gene phenotypes are dominated by non-motor symptoms, such as cognitive impairment ([@B44]).

Catechol-O-methyltransferase (COMT) is involved in catecholamine degradation ([@B72]). The Val158/108Met single nucleotide polymorphism (SNP) in COMT gene has been extensively investigated in relation to PD, as well as the cognitive dysfunctions, including five aspects: executive function, attention and working memory, language, memory, and visuospatial function ([@B23]). It contains a common functional SNP at codon 158/108 and generates a valine (Val)-to-methionine (Met) substitution (Val158Met), which results in a reduction of COMT enzyme activity and an increase in the dopamine level in the prefrontal cortex ([@B48]; [@B63]). The association between COMT genotype and cognition symptoms in subjects with PD has been checked, but the results are controversial. In their results, Barnett et al. (2008) did find a robust association between Val158Met and IQ. Healthy individuals with Val/Val have poorer scores on working memory ([@B1]). However, the other neurocognitive phenotype studies demonstrated substantial between-study heterogeneity. Dennis et al. reported that COMT val108/158met genotype has no effect on cognitive behavioral measures in healthy individuals but has an impact on neural activation patterns. Beyond that, [@B56] found no previous associations between COMT Val158Met and cognitive performance in the cohort of cognitively normal older adults. In PD, many similar explorations focusing on genetic factors in cognitive decline were also made. COMT genotype was associated with attention but not with overall cognitive status ([@B9]; [@B51]). Certainly, some studies asserted that COMT Met/Met genotype could be a predictor of faster cognitive decline in PD ([@B55]).

To systematically synthesize these disparate studies, we attempted to synthesize the evidence regarding COMT Val158/​108Met polymorphism and occurrence of PD, so much as PD with cognitive disorder through meta-analytic techniques. Therefore, the present study aimed to further our understanding of the effect of the COMT Val158/108Met variant on cognition function of PD. It would also be useful to reveal the mixed findings concerning COMT and PD in GWAS correlational research.

Methods and Materials {#s2}
=====================

Systematic review and meta-analysis were performed using the preferred reporting items for systematic review and meta-analysis statement (PRISMA) ([@B50]). The protocol for the present study was registered with the PROSPERO registry (CRD42018087323).

Search Strategy {#s2_1}
---------------

We searched major scientific databases including but not limited to PubMed, EMBASE, the Cochrane Library, Web of Science, the WanFang databases, SinoMed databases, and the CNKI up to November 2018 with different combinations of the following words: "Parkinson Disease," "Idiopathic Parkinson Disease," "catechol-O-methyltransferase" or "COMT," "rs4680," and "cognitive," "cognition," "cognition disorders," "perception," "memory," "executive," "dementia," and "attention." The search was restricted to English and Chinese language publications. We also obtained additional articles using reference lists of articles identified in the initial searches.

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

Qualiﬁed studies in this meta-analysis should satisfy the inclusion criteria:

1\) case-control studies that assessed the relationship between COMT Val^158/108^Met polymorphism and PD susceptibility or reported the association between the COMT Val^158/108^Met and cognition in PD subjects regarding the association between COMT; 2) there were sufficient data of cases and controls to calculate an odd ratio (OR) with 95% conﬁdence interval (CI); 3) the genotypes distribution in the control group was consistent with Hardy--Weinberg equilibrium (HWE); 4) the study was published in the English or the Chinese language; 5) if there were numerous studies from the same population, only the latest one was entered.

Studies were excluded for the major following reasons: 1) no PD cognitive data reported; 2) sample comprised patients with 22q11 deletion syndrome (who have only one copy of the COMT gene); 3) studies of a different COMT polymorphism, or overlap of reported data between papers; 4) animal trials, review, and the studies that did not report the genotype frequencies were ruled out.

Data Extraction {#s2_3}
---------------

Data were independently extracted by two authors according to the inclusion and exclusion criteria listed above. Disagreements were resolved through discussion with a third author. The following information from included studies was extracted: ﬁrst author, published year, country, ethnicity, sample size, average age of sample, number of male and female participants, allele frequency distribution in case and control, sample size, mean, and standard deviation for each cognitive variable by genotype group. COMT genotypes were grouped according to the presence or absence of the Val allele (Val/Val or Val/Met vs. Met/Met). The Newcastle-Ottawa Scale (NOS) was used to assess the methodological quality of each study ([@B69]).

Statistical Analyses {#s2_4}
--------------------

The HWE with an exact test was used to evaluate normal heterogeneity of the population. Six separate analyses as the allelic, recessive, dominant, homozygous, heterozygous, and additive genetic models were conducted in the present meta-analysis. Pooled odds ratios (ORs) with 95% conﬁdence intervals (95% CIs) were used to compare the relationship between COMT polymorphism and PD risk, and standardized mean differences (SMDs) with 95% CIs were calculated for continuous variables. The omnibus (Q) tests and I^2^ test were used to examine the heterogeneity among the studies. If P \> 0.10 or I^2^ \< 50%, the fixed-effect model was adopted. Otherwise, the random-effect model would be used. We made a prior assumption that the meta-analysis can be affected by study level variability determined by different inclusion criteria across RCTs, which is more appropriately addressed by a random-effects model over a fixed-effect model. The pooled OR was assessed by Z test and *P* \< 0.05 level was considered as statistically significant. Sensitivity analysis was carried out by sequentially omitting one study at a time to estimate the stability of the result. Subgroup analysis was performed to assess the influence of potential moderators. Potential publication bias was estimated using Egger's linear regression test by visual inspection of the funnel plot. All analyses were performed using Stata 12.0.

Results {#s3}
=======

Study Characteristics {#s3_1}
---------------------

After the retrieval process, 49 relevant studies met the inclusion criteria, 35 ([@B29]; [@B37]; [@B70]; [@B84]; [@B86]; [@B49]; [@B38]; [@B82]; [@B18]; [@B25]; [@B28]; [@B85]; [@B42]; [@B75]; [@B90]; [@B65]; [@B8]; [@B34]; [@B6]; [@B60]; [@B35]; [@B9]; [@B71]; [@B87]; [@B36]; [@B57]; [@B66]; [@B33]; [@B68]; [@B74]; [@B67]; [@B88]; [@B55]; [@B58]; [@B43]) of which reported the association between COMT Val158/108Met polymorphism and the risk of PD, and a total of 11,773 patients and 17,046 controls were included in this section. Four ([@B9]; [@B74]; [@B15]; Li, 2016) studies reported the association between COMT Val^158/108^Met polymorphism and cognitive dysfunction in PD, whereas the other 10 ([@B79]; [@B78]; [@B31]; [@B51]; [@B81]; [@B19]; [@B55]; [@B89]; [@B83]; [@B4]) articles mentioned the association between COMT Val158Met polymorphism and cognitive decline in PD including 1,547 PD patients. The selection process was shown in [**Figure 1**](#f1){ref-type="fig"}, and the main characteristics of the included studies are listed in [**Tables 1**](#T1){ref-type="table"}--[**3**](#T3){ref-type="table"}.

![Flow diagram of articles selection process.](fgene-10-00644-g001){#f1}

###### 

Characteristics of the included studies of the association between the COMT Val158Met polymorphism and PD susceptibility.

  First author               Year     Country    Number of   Mean age   Male/female    Case           Controls    HWE         NOS score                                                         
  -------------------------- -------- ---------- ----------- ---------- -------------- -------------- ----------- ----------- ----------- ------- ------ ------ ------- ------ ------- -------- ---
  Song et al.                2015     China      221         229        66.88          66.74          134/87      122/107     100         100     21     107    97      25     0.577   0.669    7
                             Male                134         122        −              −              −           −           63          59      12     57     52      13     0.730   0.824    
                             Female              87          107        −              −              −           −           37          41      9      50     45      12     0.631   0.698    
  Zhang et al.               2015     China      437         530        62.4(11.4)     61.6(8.7)      230/207     318/212     251         173     13     291    210     29     0.009   0.262    6
  Qi et al.                  2013     China      90          95         63.2(10.3)     64.2(10.1)     47/43       50/45       59          26      5      45     34      16     0.356   0.040    6
                             Early               44          51         −              −              −           −           28          14      2      24     18      9      0.883   0.0004   
                             Late                46          43         −              −              −           −           31          12      3      21     16      7      0.246   0.206    
  Jin et al.                 2014     China      188         111        61.3(10.3)     58.3(9.7)      98/90       54/57       108         72      8      59     46      6      0.350   0.438    7
                             Early               47          111        −              −              −           −           24          22      1      59     46      6      0.113   0.438    
                             Late                141         111        −              −              −           −           84          50      7      59     46      6      0.900   0.438    
  Ma et al.                  2018     China      152         252        67.9(9.5)      67.8(10.8)     77/75       130/122     87          57      8      145    90      17     0.734   0.553    6
  Wang et al.                2014     China      265         282        −              66.74(7.25)    −           141/141     143         107     15     150    117     15     0.386   0.199    7
  Zhao et al.                2003     China      144         188        63.3(14)       55.8(15.5)     78/66       97/91       80          54      10     98     81      9      0.830   0.129    6
  Song et al.                2014     China      237         247        −              −              146/91      133/114     109         107     21     118    102     27     0.466   0.486    6
                             Late                199         196        −              −              −           −           95          84      20     91     21      84     0.821   0.001    
                             Male                146         133        −              −              −           −           67          67      12     64     54      15     0.400   0.486    
                             Female              91          114        −              −              −           −           42          40      9      54     48      12     0.907   0.784    
  Zen et al.                 2012     China      94          104        65.12(10.2)    67.06(10.28)   58/36       60/44       33          45      16     40     50      14     0.921   0.794    7
                             Male                58          60         −              −              −           −           22          30      6      25     27      8      0.362   0.868    
                             Female              36          44         −              −              −           −           11          15      10     15     23      6      0.319   0.546    
  Xiao et al.                2017     China      143         157        65.1(8.7)      65.4(7.2)      79/64       88/69       79          56      8      91     57      9      0.637   0.985    7
                             Early               24          157        −              −              −           −           8           15      1      91     57      9      0.073   0.985    
                             Late                119         157        −              −              −           −           71          41      7      91     57      9      0.739   0.985    
  Eerolaa et al.             2002     Finland    147         137        67.2           65.8           87/60       50/87       30          71      46     31     71      35     0.786   0.595    7
  Watanabea et al.           2003     Japan      121         100        68.2           64(9)          49/72       85/15       57          47      14     47     49      4      0.377   0.043    7
  Toraman-Boutorabi et al.   2012     Iran       108         70         57.46(10.35)   55.73(11.69)   72/31       42/28       20          50      33     19     32      19     0.892   0.473    7
                             Male                72          50         −              −              −           −           13          38      21     12     19      11     0.560   0.539    
                             Female              31          28         −              −              −           −           7           12      12     7      13      8      0.253   0.710    
  Yoritaka et al.            1997     Japan      176         156        62.7(8.8)      57.9(16.2)     −           −           100         62      14     69     77      10     0.323   0.058    6
  Benitez et al.             2010     Colombia   104         136        60.1(12.6)     62.4(9.5)      61/43       63/73       47          39      17     52     68      13     0.800   0.171    7
  Xie et al.                 1997     China      70          62         64.3(9.96)     63.9(9.86)     31/39       24/38       44          21      5      37     19      6      0.277   0.150    7
  Syvanen et al.             1997     Finland    158         76         −              −              87/71       36/40       39          80      39     14     35      27     0.874   0.655    6
  Kiyohara et al.            2011     Japan      238         369        68.5(1.1)      66.6(0.85)     91/147      140/228     98          116     24     179    166     24     0.222   0.076    6
  Lee et al.                 2001     Finland    73          49         62             −              33/40       −           40          27      6      26     21      2      0.636   0.371    6
  Goudreau et al.            2002     USA        319         196        −              −              197/122     74/122      59          163     84     50     82      55     0.205   0.094    7
                             Male                191         72         −              −              −           −           39          99      53     17     37      18     0.559   0.812    
                             Female              115         115        −              −              −           −           20          64      31     33     45      37     0.186   0.203    
                             Early               164         82         −              −              −           −           26          89      49     28     37      17     0.170   0.463    
                             Late                142         105        −              −              −           −           33          74      35     22     45      38     0.613   0.209    
  Kunugi et al.              1997     Japan      109         153        −              −              55/54       75/78       46          47      16     74     70      9      0.485   0.149    6
  Hoda et al.                1996     UK         139         173        −              −              −           −           32          70      37     40     88      45     0.920   0.811    6
  Klebe et al.               2013     France     5886        10723      57.6(13.8)     60.0(10.1)     3532/2354   5388/5335   1417        2911    1558   2526   5303    2894   0.429   0.313    8
  Lynch et al.               2002     USA        100         66         60.6           46.5           71/29       30/36       29          45      25     20     30      16     0.374   0.477    7
  Hernán et al.              2002     USA        213         439        −              −              −           −           50          106     57     112    220     107    0.958   0.960    6
                             Male                101         203        −              −              −           −           26          44      31     50     102     51     0.203   0.944    
                             Female              112         236        −              −              −           −           24          62      26     62     118     56     0.255   0.487    
  Mizuta et al.              2000     Japan      171         199        66.0(8.0)      67.5(11.7)     −           −           85          71      15     88     90      21     0.975   0.776    7
  Shih et al.                2013     China      260         100        71.4(0.787)    −              137/123     −           100         90      70     30     46      24     0.001   0.443    6
  Kalinderi et al.           2008     Greece     134         125        61.7           71.7           −           −           48          54      32     40     49      36     0.035   0.016    7
  Paul et al.                2016     USA        341         483        −              −              −           −           83          174     84     127    229     127    0.704   0.255    7
  Bialecka et al.            2008     Poland     322         357        64.0(10.2)     72.5(9.7)      191/131     207/150     78          160     84     80     166     111    0.916   0.234    8
                             Early               101         357        −              −              −           −           24          46      31     80     166     111    0.394   0.234    
                             Late                221         357        −              −              −           −           54          114     53     80     166     111    0.637   0.234    
  Białecka et al.            2012     Poland     57          64         −              −              −           −           38          15      4      38     23      3      0.167   0.839    6
  Wu et al.                  2001     China      222         191        67.2(9.1)      65.8(9.2)      162/62      145/52      125         79      18     117    62      12     0.277   0.336    6
                             Early               37          34         −              −              −           −           25          16^a^          33     15^a^          −       −        
                             Late                187         163        −              −              −           −           100         81^a^          86     57^a^          −       −        
                             Male                160         140        −              −              −           −           32          30^a^          28     23^a^          −       −        
                             Female              62          61         −              −              −           −           93          67             91     49^a^          −       −        
  Rowe et al.                2010     UK         50          82         64.9(9.0)      66.2(7.3)      −           −           16          18      15     22     36      22     0.064   0.371    7
  Shao et al.                2005     China      140         144        −              −              80/60       74/70       84          41      15     75     62      7      0.007   0.264    7
  Xu et al.                  2002     China      144         201        −              −              −           −           80          54      10     105    86      10     0.830   0.149    7
                             Early               47          161        −              −              −           −           29          17      1      84     68      9      0.405   0.317    
                             Late     China      97          40         −              −              −           −           51          37      9      21     18      1      0.547   0.206    

HWE, Hardy-Weinberg equilibrium, a; GA plus AA.

###### 

Characteristics of the included studies of the association between the COMT Val158Met polymorphism and cognitive dysfunction in PD.

  First author   Year   Country   Number of   Mean age   Male/female    PD-NC     PD-CI   HWE   NOS score                                    
  -------------- ------ --------- ----------- ---------- -------------- --------- ------- ----- ----------- ----- ----- ---- ------- ------- ---
  Dai            2015   China     702         385        63.0           631/456   344     291   67          192   162   33   0.632   0.887   7
  Li             2014   China     68          71         59.64(11.61)   78/61     35      28    5           40    24    7    0.852   0.246   7
  Wang           2014   China     91          75^a^      66.39          ------    52      32    7           34    36    5    0.510   0.264   7
  Wang           2014   China     91          99^b^      66.39          ------    52      32    7           57    39    3    0.510   0.226   6
  Białecka       2012   Poland    29          13         ------         ------    20      5     4           9     4     0    0.006   0.512   7

PD-NC, PD with no cognitive impairment; PD-CI, cognitive impairment in PD; a, mild cognitive impairment in PD; b, dementia in PD.

###### 

Characteristics of the included studies of the association between the COMT Val158Met and neuro-cognition in PD.

  Author            Year   Country           Subjects   Ethnicity    %Male   Age   Met/Met   Val/Met   Val/Val   Phenotype                                        
  ----------------- ------ ----------------- ---------- ------------ ------- ----- --------- --------- --------- ----------- ------- ----- -------- ------- ----- ----------
  **UPDRS**                                                                                                                                                       
  Wu                2012   UK                PD         Caucasians   65      63    25.60     8.50      10        ---         ---     ---   26.80    12.10   10    UPDRS
  Xiao              2017   CHINA             PD         Asian        ---     58    31.00     11.90     8         22.40       12.10   56    25.80    11.90   79    UPDRS
  Morley            2012   USA               PD         Caucasians   74      71    24.00     11.00     56        ---         ---     ---   22.00    11.00   156   UPDRS
  Fallon            2015   Netherlands       PD         Caucasians   67      64    31.00     11.00     108       33.00       12.00   184   31.00    9.00    80    UPDRS
  Williams-Gray     2007   UK                PD         Caucasians   65      65    26.10     9.40      16        ---         ---     ---   22.50    10.50   16    UPDRS
  Zhang             2016   CHINA             PD         Asian        58      60    30.47     12.28     8         30.00       8.75    105   27.26    14.05   137   UPDRS
  Williams-Gray     2008   UK                PD         Caucasians   62      64    26.80     10.00     13        ---         ---     ---   23.00    10.80   16    UPDRS
  Bäckström         2017   Sweden            PD         Caucasians   59      69    24.94     17.65     42        25.7        12.13   64    30.07    10.19   26    UPDRS
  Paul              2016   USA               PD         Caucasians   55      66    20.2      9.3       63        ---         ---     ---   18.8     9.1     168   UPDRS
  Hoogland          2010   The Netherlands   PD         Caucasians   54      66    20.00     9.00      37        20          10      84    18.00    9.00    32    UPDRS
  **MMSE**                                                                                                                                                        
  Wu                2012   UK                PD         Caucasians   65      63    29.60     0.50      10        ---         ---     ---   29.60    0.70    10    MMSE
  Fallon            2015   Netherlands       PD         Caucasians   67      64    28.00     2.00      108       29.00       1.00    184   28.00    2.00    80    MMSE
  Williams-Gray     2007   UK                PD         Caucasians   65      65    28.70     0.80      16        ---         ---     ---   28.90    1.20    16    MMSE
  Zhang             2016   CHINA             PD         Asian        58      60    26.75     3.45      8         26.74       3.50    105   26.93    3.03    137   MMSE
  Williams-Gray     2008   UK                PD         Caucasians   62      64    28.80     0.70      13        ---         ---     ---   28.90    1.20    16    MMSE
  Bäckström         2017   Sweden            PD         Caucasians   59      69    28.60     1.40      42        28.70       1.40    64    28.70    1.30    26    MMSE
  Paul              2016   USA               PD         Caucasians   55      66    28.20     2.60      63        ---         ---     ---   28.30    1.90    168   MMSE
  **Combined IQ**                                                                                                                                                 
  Wu                2012   UK                PD         Caucasians   65      63    120.20    4.40      10        ---         ---     ---   114.30   8.20    10    NART
  Fallon            2015   Netherlands       PD         Caucasians   67      64    102.00    20.00     108       103.00      18.00   184   103.00   18.00   80    NART
  Williams-Gray     2007   UK                PD         Caucasians   65      65    114.70    6.20      16        ---         ---     ---   113.10   7.30    16    NART
  Zhang             2016   CHINA             PD         Asian        58      60    92.56     16.90     8         97.99       14.94   105   100.88   14.84   137   WAIS-VIQ
  Zhang             2016   CHINA             PD         Asian        58      60    83.19     18.39     8         94.98       14.24   105   95.71    12.93   137   WAIS-PIQ
  Zhang             2016   CHINA             PD         Asian        58      60    85.24     18.29     8         95.74       14.94   105   97.68    14.16   137   WAIS-FIQ
  Williams-Gray     2008   UK                PD         Caucasians   62      64    114.50    6.60      13        ---         ---     ---   114.20   6.90    16    NART
  Hoogland          2010   The Netherlands   PD         Caucasians   54      66    105.00    17.00     37        100         18      84    102.00   20.00   32    NART

UPDRS, Unified Parkinson's Disease Rating Scale; MMSE, Mini Mental State Examination; NART, National Adult Reading Test; WAIS, Wechsler Adult Intelligence Scale; VIQ, Verbal Intelligence Quotient; FIQ, Full Intelligence Quotient; PIQ, Performance Intelligence Quotient.

As shown in [**Table 1**](#T1){ref-type="table"}, 15 studies were performed on Caucasians. Of the 35 studies, 20 focused only on Asian. Six studies explored the relationships of alleles or genotypes with age at disease onset. Meanwhile, six studies explored the relationships with gender. Nevertheless, three studies were deviated according to HWE of genotype frequencies among the controls.

As shown in [**Table 2**](#T2){ref-type="table"}, four case-control studies reported the association between COMT polymorphism and cognitive dysfunction in PD, including 890 PD-NC (PD, no cognitive impairment) and 643 PD-CI (PD, cognitive impairment includes mild cognitive impairment and dementia of PD) . Three studies involved the Chinese population. In addition, one was from Poland. The genotype frequencies in all studies fully complied with HWE.

[**Table 3**](#T3){ref-type="table"} identifies 10 studies included in the meta-analytic to compare cognitive effects between groups of Met homozygotes and Val carriers with PD on cognitive scores. The table includes information about sample characteristics (gender distribution, age, genotype frequencies, ethnicity, etc.) and measures administered.

Meta-Analysis of the Association Between COMT Val158/108Met and PD Susceptibility {#s3_2}
---------------------------------------------------------------------------------

Overall, there were 11,428 cases and 16,726 controls included in the analysis. The ORs and 95% CIs in random- and fixed-effect models were calculated according to the values of Q test and I^2^. There was no significant association between COMT Val158/108Met polymorphism and PD susceptibility in the whole population under allelic (OR, 1.01; 95% CI, 0.97--1.04; *P* = 0.667), recessive (OR, 0.99; 95% CI, 0.93--1.05; *P* = 0.792), dominant (OR, 0.99; 95% CI, 0.94--1.04; *P* = 0.671), homozygous (OR, 1.00; 95% CI, 0.93--1.08; *P* = 0.985), heterozygous (OR, 0.99; 95% CI, 0.93--1.04; *P* = 0.655), and additive genetic models (OR, 1.00; 95% CI, 0.97--1.03; *P* = 0.790) ([**Figure 2**](#f2){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}). To investigate the exact consequence of the relationship between COMT polymorphism and PD susceptibility, subgroup analyses by ethnicity were performed. No significant association was found in any subgroup under different genetic models between PD risk and COMT genotype ([**Figure 2**](#f2){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}).

![Forest plots for the association between COMT Val158/108Met polymorphism and PD risk. **(A)** Addictive genetic model (A vs G). **(B)** Dominant genetic model (AA +GA vs GG). **(C)** Homozygous model (AA vs GG). **(D)** Heterozygous model (GA vs. GG). **(E)** Recessive genetic model (AA vs. GG + GA). **(F)** Allelic genetic model (A allele distribution frequency of COMT Val158Met gene polymorphism).](fgene-10-00644-g002){#f2}

###### 

Summary of meta-analysis of association between COMT Val158/108Met polymorphism and PD risk.

  Genetic model                    Pooled OR (95% CI)   Z value   P value   P~Heterogeneity~ (I^2^%)   Publication bias   
  -------------------------------- -------------------- --------- --------- -------------------------- ------------------ -------
  **Allelic genetic model**                                                                                               
  ** Ethnicity**                                                                                                          
   Asian subgroup                  1.01(0.94,1.09)      0.21      0.833     0.530(0.0%)                0.00               0.998
   Caucasian subgroup              1.01(0.97,1.05)      0.38      0.708     0.507(0.0%)                −0.39              0.291
  ** Gender**                                                                                                             
   Male                            0.95(0.80,1.11)      0.67      0.502     0.942(0.0%)                −1.12              0.396
   Female                          0.90(0.75,1.07)      1.25      0.213     0.962(0.0%)                −1.12              0.112
  ** Onset of PD**                                                                                                        
   Early                           0.87(0.62,1.23)      0.78      0.436     0.028(63.1%)               0.01               0.998
   Late                            1.20(1.03,1.40)      2.38      0.017     0.435(0.0%)                0.38               0.792
  **Recessive genetic model**                                                                                             
  ** Ethnicity**                                                                                                          
   Asian subgroup                  1.09(0.92,1.30)      0.98      0.326     0.356(8.3%)                0.69               0.564
   Caucasian subgroup              0.98(0.92,1.04)      0.63      0.527     0.586(0.0%)                0.36               0.302
  ** Gender**                                                                                                             
   Male                            1.04(0.78,1.40)      0.28      0.776     0.778(0.0%)                −2.09              0.076
   Female                          1.00(0.74,1.36)      0.03      0.980     0.566(0.0%)                1.94               0.107
  ** Onset of PD**                                                                                                        
   Early                           1.07(0.75,1.52)      0.36      0.716     0.423(0.0%)                −0.98              0.263
   Late                            0.71(0.54,0.94)      2.38      0.017     0.457(0.0%)                0.79               0.362
  **Dominant genetic model**                                                                                              
  ** Ethnicity**                                                                                                          
   Asian subgroup                  0.96(0.87,1.06)      0.80      0.423     0.411(3.7%)                −0.80              0.483
   Caucasian subgroup              1.00(0.94,1.07)      0.03      0.973     0.268(16.9%)               0.41               0.333
  ** Gender**                                                                                                             
   Male                            1.07(0.86,1.32)      0.59      0.555     0.979(0.0%)                0.99               0.148
   Female                          1.21(0.97,1.52)      1.71      0.087     0.865(0.0%)                −0.52              0.613
  ** Onset of PD**                                                                                                        
   Early                           1.28(0.98,1.68)      1.79      0.073     0.016(64.0%)               3.04               0.465
   Late                            0.91(0.74,1.10)      0.99      0.323     0.550(0.0%)                −1.96              0.198
  **Homozygous genetic model**                                                                                            
  ** Ethnicity**                                                                                                          
   Asian subgroup                  1.05(0.87,1.26)      0.53      0.594     0.373(6.9%)                0.77               0.554
   Caucasian subgroup              0.99(0.92,1.08)      0.21      0.836     0.391(5.5%)                0.56               0.134
  ** Gender**                                                                                                             
   Male                            1.07(0.75,1.50)      0.36      0.720     0.822(0.0%)                −0.15              0.926
   Female                          1.26(0.87,1.81)      1.24      0.216     0.917(0.0%)                0.74               0.455
  ** Onset of PD**                                                                                                        
   Early                           1.25(0.82,1.92)      1.04      0.297     0.064(55.1%)               −0.96              0.546
   Late                            0.73(0.52,1.02)      1.87      0.062     0.493(0.0%)                0.59               0.556
  **Heterozygous genetic model**                                                                                          
  ** Ethnicity**                                                                                                          
   Asian subgroup                  0.95(0.86,1.04)      1.11      0.267     0.277(14.7%)               −1.44              0.211
   Caucasian subgroup              1.01(0.94,1.08)      0.23      0.819     0.212(22.3%)               0.31               0.477
  ** Gender**                                                                                                             
   Male                            1.11(0.86,1.43)      0.81      0.415     0.807(0.0%)                1.77               0.196
   Female                          1.32(1.00,1.74)      1.93      0.053     0.517(0.0%)                −0.93              0.569
  ** Onset of PD**                                                                                                        
   Early                           1.30(0.97,1.75)      1.73      0.084     0.019(66.0%)               5.67               0.329
   Late                            0.89(0.71,1.13)      0.95      0.343     0.770(0.0%)                −1.58              0.201
  **Additive genetic model**                                                                                              
  ** Ethnicity**                                                                                                          
   Asian subgroup                  0.99(0.93,1.07)      0.18      0.861     0.952(0.0%)                −0.05              0.958
   Caucasian subgroup              1.00(0.96,1.03)      0.21      0.832     0.993(0.0%)                0.22               0.273
  ** Gender**                                                                                                             
   Male                            1.03(0.89,1.19)      0.38      0.702     0.995(0.0%)                0.28               0.713
   Female                          1.06(0.91,1.24)      0.75      0.453     0.997(0.0%)                0.60               0.150
  ** Onset of PD**                                                                                                        
   Early                           1.07(0.90,1.27)      0.77      0.442     0.325(14.0%)               0.03               0.989
   Late                            0.90(0.79,1.03)      1.50      0.134     0.752(0.0%)                −0.47              0.614

Furthermore, to better explore the role of COMT in PD, we performed the subgroup analysis by the gender and onset of PD. As noted previously, a total of six case-control studies have been reported regarding the association between COMT polymorphism and gender of PD susceptibility. In the gender subgroup, no significant association was detected under all the genetic models, except that a borderline significant association was detected of female PD in the heterozygous genetic models (OR, 1.32; 95% CI, 1.00--1.74; *P* = 0.053) in the pooled populations ([**Figure 3**](#f3){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}). In addition, the pooled analyses indicated that there was a signiﬁcant association between COMT polymorphism and late onset of PD susceptibility under recessive (OR, 0.71; 95% CI, 0.54--0.94; *P* = 0.017) and allelic genetic models (OR, 1.20; 95% CI, 1.03--1.40; *P* = 0.017) ([**Figure 4**](#f4){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}).

![Forest plots for the association between COMT Val158/108Met polymorphism and PD risk-stratified by gender. **(A)** Addictive genetic model (A vs G). **(B)** Dominant genetic model (AA +GA vs GG). **(C)** Homozygous model (AA vs GG). **(D)** Heterozygous model (GA vs. GG). **(E)** Recessive genetic model (AA vs. GG + GA). **(F)** Allelic genetic model (A allele distribution frequency of COMT Val158Met gene polymorphism).](fgene-10-00644-g003){#f3}

![Forest plots for the association between COMT Val158/108Met polymorphism and PD risk-stratified by onset of PD. **(A)** Addictive genetic model (A vs G). **(B)** Dominant genetic model (AA +GA vs GG). **(C)** Homozygous model (AA vs GG). **(D)** Heterozygous model (GA vs. GG). **(E)** Recessive genetic model (AA vs. GG + GA). **(F)** Allelic genetic model (A allele distribution frequency of COMT Val158Met gene polymorphism).](fgene-10-00644-g004){#f4}

Sensitivity analysis was carried out for this meta-analysis by omitting one study at a time to assess the influence of any single study. When removing one study at the time, there was no significant change in the pooled ORs.

The publication bias of the studies was evaluated by Egger's test. The results of Egger's test also suggested that the possibility of publication bias was low ([**Table 4**](#T4){ref-type="table"}).

Meta-Analysis of the Association Between COMT Val158/108Met and PD-CI Susceptibility {#s3_3}
------------------------------------------------------------------------------------

From the four included studies, we pooled data from 1,533 subjects, including 890 PN-NC and 643 PD-CI. There was no significant association between COMT Val^158/108^Met polymorphism and PD in the whole population under allelic (OR, 1.02; 95% CI, 0.87--1.20; *P* = 0.788), recessive (OR, 0.83; 95% CI, 0.58--1.20; *P* = 0.334), dominant (OR, 1.02; 95% CI, 0.84--1.25; *P* = 0.831), homozygous (OR, 0.85; 95% CI, 0.58--1.24; *P* = 0.402), heterozygous (OR, 1.06; 95% CI, 0.86--1.32; *P* = 0.561), and additive genetic models (OR, 0.98; 95% CI, 0.85--1.14; *P* = 0.836) ([**Figure 5**](#f5){ref-type="fig"}).

![Forest plots for the association between COMT Val158/108Met polymorphism and cognitive impairment in PD. **(A)** Addictive genetic model (A vs G). **(B)** Dominant genetic model (AA +GA vs GG). **(C)** Homozygous model (AA vs GG). **(D)** Heterozygous model (GA vs. GG). **(E)** Recessive genetic model (AA vs. GG + GA). **(F)** Allelic genetic model (A allele distribution frequency of COMT Val158Met gene polymorphism). a, PD-NC vs PD-MCI; b, PD-NC vs PDD.](fgene-10-00644-g005){#f5}

Sensitivity analysis was carried out for this meta-analysis by omitting one study at a time to assess the influence of any single study and found no significant change in the pooled ORs. The publication bias of the studies was evaluated by Egger's test. The results of Egger's test also suggested that the possibility of publication bias was low (data not shown).

Meta-Analysis of the Cognitive Effects of the COMT Val158/108Met Polymorphism in PD {#s3_4}
-----------------------------------------------------------------------------------

### UPDRS III {#s3_4_1}

Ten independent studies with 1,574 PD patients contributed to the meta-analysis. There was no evidence of between-study heterogeneity (Q-statistic = 13.30; *P* = 0.503; *I* ^2^ = 0%), and random effects analysis indicated no evidence of association (SMD, −0.07; 95% CI, −0.18; 0.04; *P* = 0.206) ([**Figure 6A**](#f6){ref-type="fig"}).

![The forest plot for differences between Val carriers and Met homozygotes on the cognitive effects. **(A)** UPDRS III. **(B)** MMSE. **(C)** IQ Score. UPDRS, Unified Parkinson's Disease Rating Scale; MMSE, Mini Mental State Examination; CI, confidence interval; OR, odds ratio. a, Val/Val vs Met/Met; b, Val/Met vs Met/Met.](fgene-10-00644-g006){#f6}

The results of Egger's test also suggested that the possibility of publication bias was high (*P* = 0.017). However, a subgroup analysis comparing the Asians versus Caucasians was significant, indicating that homozygotes for the Met158 allele have higher UPDRS III scores than the Val allele carriers in Asian population (SMD, −0.45; 95% CI, −0.81 to −0.09; *P* = 0.016). The publication bias of the studies was evaluated by Egger's test. The results of Egger's test also suggested that publication bias was low in Asians (*P* = 0.169) or Caucasians (*P* = 0.259).

### MMSE {#s3_4_2}

Seven independent samples with 835 PD patients contributed to the meta-analysis. There was evidence of between-study heterogeneity (Q-statistic = 21.32; *P* = 0.011; I^2^ = 57.8%), and random effects analysis indicated no evidence of association (SMD, 0.14; 95% CI, −0.08 to 0.37; *P* = 0.203). The results of Egger's test also suggested that the possibility of publication bias was low (*P* = 0.306). In addition, subgroup analysis by ethnicity indicated that no association was detected in Asian population or Caucasian population ([**Figure 6B**](#f6){ref-type="fig"}).

### IQ Score {#s3_4_3}

Six independent samples with 856 PD patients contributed to the meta-analysis. Combined IQ score included the National Adult Reading Test (NART) and Wechsler Adult Intelligence Scale (WAIS). There was evidence of between-study heterogeneity (Q statistic = 27.82, *P* = 0.006, *I* ^2^ = 56.9%), and random effects analysis indicated no evidence of association (SMD, 0.18; 95% CI, −0.05 to 0.41; *P* = 0.116).

The results of Egger's test also suggested that the possibility of publication bias was low (*P* = 0.206), although subgroup analysis by ethnicity detected that homozygotes for the Met158 allele have lower IQ scores than the Val allele carriers in Asian population (SMD, 0.70; 95% CI, 0.41--1.00; *P* \< 0.001). Considering that the sample size of Asians is limited, one needs to be cautious of the result and large-scale studies need to clarify the significance of the conclusion ([**Figure 6C**](#f6){ref-type="fig"}).

Discussion {#s4}
==========

In the present meta-analysis, we did not find any statistical association between the COMT polymorphism with risks of PD in the overall population, even though five different models were utilized. In the new stratified analyses of population-based studies on different ethnicities (Asians and Caucasians), no association with COMT Val158/108Met polymorphism was shown. Intriguingly, subgroup analyses focusing on gender and onset time demonstrated that COMT Val158/108Met polymorphism has a major impact on the female in the heterozygous genetic model and the late onset in recessive and allelic genetic models. In addition, there was also a faint association between genotype and abstract thought (IQ: WAIS, NART). We also found no evidence of significant publication bias.

For the deep analysis, gender should be considered as a main factor to explore the COMT genotype with cognition in PD. However, not enough data could be obtained for accurate analysis. Sannino et al. (2015, 2017) reported that female COMT Met carriers show reduced cortical thickness after puberty and closely correlated with cognitive functions, which indicates that there is a change of brain structure that can increase the risk of PD. These findings suggest that it is important to appreciate the genetic and gender difference in the patient population. In the context of COMT Val158/108Met polymorphism, female PD patients should be assessed for cognitive function alone in future studies.

Our studies indicated that female carriers of the Met allele of COMT may be at an increased risk for developing PD. The question remains: How could the COMT genotype influence PD development in a gender-specific way? The COMT gene is located on chromosome 22, band q11.2 ([@B80]), and its encoded enzyme degrades a broad group of physiological catechols. This is one of the main mechanisms of terminating DA action in the synapse, together with DA reuptake by the DAT and DA diffusion out of the synapse ([@B3]; [@B46]). It is reported that Val is a predominant factor that determines higher COMT activity, which presumably leads to lower synaptic dopamine levels ([@B12]). The Met/Met genotype causes the change in thermos ability of the enzyme, which is often characterized by decreased enzymatic activity even at 37°C ([@B11]). It may be that women's hormone levels and thermoregulation differ from men, which illustrates a potential reason why COMT genotype is associated with PD in women alone. Some compelling evidence also demonstrated that estrogens may modulate COMT gene expression and protein activity *via* estrogen receptor function ([@B64]). As mentioned above, there is another possibility that female COMT Met carriers may remodel brain structures involved in the neurobiology of PD ([@B61]).

Importantly, it was also reported that the Val allele had a significant effect on the age of onset of PD ([@B32]). This genotype may confer a greater risk of PD because of higher catecholaminergic metabolism, leading to an accelerated use of endogenous dopamine reservoirs as well as activating catabolism of COMT substrates ([@B8]). In our analysis, the result was consistent with the previous literature. Carriers of the Val allele of COMT Val158/108Met polymorphism may be at an increased risk for late-onset PD.

Cognitive disorders associated with PD could be so mild that they are under-recognized and do not alter daily living activities ([@B54]). A wealth of evidence has shown that the circuitry of dorsolateral prefrontal cortex and the front striatal ([@B7]) supports various advanced brain functions ([@B2]). It has been also shown that regulating the level of DA can improve the specific cognitive function relying on this circuitry ([@B39]). [@B76] also identified that the DA level in prefrontal cortex was strongly related to the performance of working memory. Yerkes--Dodson type U-shape relationship governs the DA modulation of neural function, which means reduction or excessive increases of DA will selectively impair specific cognitive function ([@B59]). Further evidence demonstrating the role of DA on cognitive function in PD has been obtained from the study of polymorphisms of COMT, which regulates prefrontal cortical DA turnover, as well as activation in prefrontal--striatal regions ([@B53]).

In our analysis of association between cognitive and motor abilities in PD and COMT Val158/108Met polymorphism, there is no positive evidence. During the seriatim heterogeneity test and sensitivity analysis, we found one study that if we removed from the analysis, the results would have been reversed. The eccentric study was about the European population. First and foremost, we made a subgroup analysis of ethnics. The result showed that the relationship between COMT and UPDRS III, IQ was appreciable in Asian, but not Europeans. Asians with Met carrier conferred an increased risk of high UPDRS III score, meaning a more severe motor impairment. Meanwhile, Asian patients with Met/Met genotype performed significantly worse on abstract thought (IQ: WAIS, NART). After further analysis on these two studies, we found that the levodopa dose was lower in subjects with Met/Met genotype than Val/Val group. However, in other studies, almost all PD patients with Met/Met genotype took more LODA. Given the change in the results before and after inclusion, LODA dose was a major factor and concern. It was reported that the relationship between prefrontal function and dopamine levels follows an inverted U-shaped curve ([**Figure 7**](#f7){ref-type="fig"}) ([@B79]). According to this theory, we speculated that, among PD patients, those with low activity COMT (Met/Met alleles) who take more LODA have worse performance in motor and cognition because of excessive DA levels. This is believed to contribute to impaired cognitive performance in prefrontal regions, which explains the reason of disruptive changes when one study was omitted. To sum up, factors about dosage and type of anti-PD medication should account for many reasons. Dopamine supplements may mask some linking of COMT polymorphisms and cognitive function. Studies have confirmed that high doses of dopamine reduce the expression of dopamine transporters in the prefrontal cortex, which could lead to cumulative toxicity of dopamine and make patients appear to have cognitive impairment like the patients with low-activity COMT. In other words, if PD patients with low-activity COMT use large-dose levodopa for a long time, cognitive impairment can be more severe. However, even if the use and types of anti-PD drugs have been taken into account, we could not complete this analysis due to the uncertainty and ambiguity of information.

![Diagram of inverted U-shaped relationship between prefrontal function and dopamine levels.](fgene-10-00644-g007){#f7}

The Val158/108Met polymorphism remains a plausible candidate that may contribute to cognitive function deficits in PD. Although the results do not meet our expectations, it does not negate the need for scientific rigor in both the analysis and the reporting of results. At the very least, we cannot exclude the possibility that COMT genotype has a small influence on cognitive phenotypes and PD susceptibility in women. These results are partly in agreement with the previous meta-analysis, which reported that there is a significant association between COMT rs4680 and the risk for PD in the total series, as well as homozygosity for the low-activity allele in the Asiatic population ([@B32]). In addition, our analysis also further revealed the relationship between COMT genotype and PD of female and late onset. Meanwhile, in the aspect of cognition of PD, it also gives some risk analysis and discussion.

There are several potential limitations in the present meta-analysis. First, there is marginal significance among female PD patients, which encourages us; further research on the association of gender of PD and COMT Val158/108Met polymorphism should be carried out. Second, sample size limited our ability to investigate the accuracy of association of COMT Val158/108Met polymorphism and cognitive dysfunctions in PD. Additionally, limited data were obtained to explore the COMT genotype and cognition in early or late onset of PD. Due to the uneven nature of population genotype frequencies in different ethnic groups, the association of COMT Val158/108Met polymorphism and cognitive dysfunctions in PD needs further confirmation. The cognition scale indicators were multitudinous, and we were underpowered to test the combined effect in the current sample. Lastly, more studies are desirable in COMT polymorphism studies; also, the type and dose of anti-PD drug should be included specifically.

Our findings highlight the impact that COMT genetic factors can have on the susceptibility of PD and cognitive performance, specifically differences in female, late-onset PD patients, and IQ.

Conclusion {#s5}
==========

In summary, the results of our meta-analysis indicated that the COMT Val158/108Met polymorphism may be associated with the risk for PD in female or late-onset PD. Meanwhile, Met/Met carriers of Asian population performed significantly worse than the Val allele carriers in IQ score and UPDRS III. Considering the above potential limitation, these conclusions need to be further confirmed in future research.
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